Risk of intestinal involvement in mucocutaneous-onset Behçet’s disease: data from the AIDA network registry - Summary - MDSpire

Risk of intestinal involvement in mucocutaneous-onset Behçet’s disease: data from the AIDA network registry

  • By

  • Antonio Vitale

  • Valeria Caggiano

  • Jessica Sbalchiero

  • Francesco Gavioli

  • Giuseppe Lopalco

  • Gaafar Ragab

  • Silvana Guerriero

  • Ibrahim Almaglouth

  • Abdurrahman Tufan

  • Roberto Giacomelli

  • Haner Direskeneli

  • Piero Ruscitti

  • Gülen Hatemi

  • Francesco Carubbi

  • Ezgi Deniz Batu

  • Seza Ozen

  • Jurgen Sota

  • Henrique Ayres Mayrink Giardini

  • Micol Frassi

  • Petros P Sfikakis

  • Maria Morrone

  • Federica Gatti

  • Amina Maher

  • Ayman Abdel-Monem Ahmed Mahmoud

  • Rosanna Dammacco

  • Hamit Kucuk

  • Riza Can Kardas

  • Ibrahim Yahya Cakir

  • Letizia Pia di Corcia

  • Fatma Alibaz Öner

  • Gizem Sevik

  • Martina Gentile

  • Alican Karakoc

  • Alessia Alunno

  • Hulya Ercan Emreol

  • Francesca Crisafulli

  • Maria Tektonidou

  • Francesco Ciccia

  • Maissa Thabet

  • Serena Bugatti

  • Alessandra Milanesi

  • Maria Sole Chimenti

  • Benedetta Monosi

  • Matteo Piga

  • Alberto Floris

  • Andrea Hinojosa-Azaola

  • Guillermo Arturo Guaracha-Basañez

  • Cecilia Beatrice Chighizola

  • José Hernández-Rodríguez

  • Marco Cattalini

  • Marcello Govoni

  • Ombretta Viapiana

  • Adele Civino

  • Daniela Opris-Belinski

  • Carla Gaggiano

  • Rosaria Talarico

  • Annarita Giardina

  • Giacomo Emmi

  • Piercarlo Sarzi Puttini

  • Maria Cristina Maggio

  • Paola Parronchi

  • Piero Portincasa

  • Alejandra de-la-Torre

  • Juanita Cardona-López

  • Stefano Gentileschi

  • Angela Mauro

  • Gian Domenico Sebastiani

  • Maria Francesca Gicchino

  • Ali Şahin

  • Donato Rigante

  • Emre Bilgin

  • Emanuela Del Giudice

  • Luciana Breda

  • Amato De Paulis

  • Alberto Lo Gullo

  • Şükran Erten

  • Samar Tharwat

  • Lampros Fotis

  • Maier Armin

  • Antonella Insalaco

  • Anastasios Karamanakos

  • Alessandro Conforti

  • Özgül Soysal Gündüz

  • Abdelhfeez Moshrif

  • Francesca Li Gobbi

  • Stefania Costi

  • Elena Bartoloni

  • Patrizia Barone

  • Serena Guiducci

  • Andrés González-García

  • Inés Hernanz Rodriguez

  • Giovanni Conti

  • Annamaria Iagnocco

  • Fatos Önen

  • Sulaiman M. Al-Mayouf

  • Ali İbrahim Hatemi

  • Alberto Balistreri

  • Claudia Fabiani

  • Luca Cantarini

  • May 13, 2026

  • 0 min

Share

Objective:

To determine demographic and clinical variables, such as age, sex, and specific symptoms, linked to subsequent gastrointestinal involvement in individuals exhibiting only mucocutaneous signs during the early phases of Behçet’s disease.

Key Findings:
  • 14% of patients with purely mucocutaneous onset experienced intestinal involvement over time.
  • Ocular involvement likelihood increased in patients with intestinal manifestations (OR: 3.02, 95% CrI: 1.24–6.08).
  • Minor aphthous ulcers provided a protective effect against intestinal involvement (OR: 0.47, 95% CrI: 0.22–0.98).
  • Major aphthous ulcers heightened the risk of gastrointestinal involvement (OR: 3.25, 95% CrI: 1.50–7.02).
  • Specific combinations of mucocutaneous symptoms significantly increased the likelihood of intestinal manifestations.
Interpretation:

Significant oral aphthosis is a key indicator of later gastrointestinal involvement in Behçet’s disease patients with initial mucocutaneous manifestations, highlighting the need for careful monitoring to prevent complications.

Limitations:
  • Restricted sample size may limit generalizability.
  • Potential biases in self-reported data could affect the reliability of findings.
Conclusion:

Gastrointestinal involvement is associated with increased risk of ocular inflammation, necessitating vigilant multidisciplinary oversight for at-risk patients.

Original Source(s)

Risk of intestinal involvement in mucocutaneous-onset Behçet’s disease: data from the AIDA network registry

  • by Antonio Vitale, Valeria Caggiano, Jessica Sbalchiero, Francesco Gavioli, Giuseppe Lopalco, Gaafar Ragab, Silvana Guerriero, Ibrahim Almaglouth, Abdurrahman Tufan, Roberto Giacomelli, Haner Direskeneli, Piero Ruscitti, Gülen Hatemi, Francesco Carubbi, Ezgi Deniz Batu, Seza Ozen, Jurgen Sota, Henrique Ayres Mayrink Giardini, Micol Frassi, Petros P Sfikakis, Maria Morrone, Federica Gatti, Amina Maher, Ayman Abdel-Monem Ahmed Mahmoud, Rosanna Dammacco, Hamit Kucuk, Riza Can Kardas, Ibrahim Yahya Cakir, Letizia Pia di Corcia, Fatma Alibaz Öner, Gizem Sevik, Martina Gentile, Alican Karakoc, Alessia Alunno, Hulya Ercan Emreol, Francesca Crisafulli, Maria Tektonidou, Francesco Ciccia, Maissa Thabet, Serena Bugatti, Alessandra Milanesi, Maria Sole Chimenti, Benedetta Monosi, Matteo Piga, Alberto Floris, Andrea Hinojosa-Azaola, Guillermo Arturo Guaracha-Basañez, Cecilia Beatrice Chighizola, José Hernández-Rodríguez, Marco Cattalini, Marcello Govoni, Ombretta Viapiana, Adele Civino, Daniela Opris-Belinski, Carla Gaggiano, Rosaria Talarico, Annarita Giardina, Giacomo Emmi, Piercarlo Sarzi Puttini, Maria Cristina Maggio, Paola Parronchi, Piero Portincasa, Alejandra de-la-Torre, Juanita Cardona-López, Stefano Gentileschi, Angela Mauro, Gian Domenico Sebastiani, Maria Francesca Gicchino, Ali Şahin, Donato Rigante, Emre Bilgin, Emanuela Del Giudice, Luciana Breda, Amato De Paulis, Alberto Lo Gullo, Şükran Erten, Samar Tharwat, Lampros Fotis, Maier Armin, Antonella Insalaco, Anastasios Karamanakos, Alessandro Conforti, Özgül Soysal Gündüz, Abdelhfeez Moshrif, Francesca Li Gobbi, Stefania Costi, Elena Bartoloni, Patrizia Barone, Serena Guiducci, Andrés González-García, Inés Hernanz Rodriguez, Giovanni Conti, Annamaria Iagnocco, Fatos Önen, Sulaiman M. Al-Mayouf, Ali İbrahim Hatemi, Alberto Balistreri, Claudia Fabiani, Luca Cantarini

  • May 13, 2026

Related Content

Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort study

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting